MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

April 8, 2024

https://www.globenewswire.com/news-release/2024/04/08/2859402/0/en/MiNK-Therapeutics-Announces-Promising-Preclinical-Activity-of-MiNK-215-Against-Colorectal-Cancer-Liver-Metastases-at-AACR.html

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting in San Diego, CA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.